HPAB-1045-FY is a recombinant humanized antibody that targets CD37. The humanized versions of HPAB-1045-FY display comparable binding to Ramos cells as the original antibody, suggesting that humanization does not diminish its ability to bind to the CD37 antigen on cells. Humanized anti-CD37 antibodies, along with pharmaceutical compositions incorporating them, have proven to be beneficial for treating B cell malignancies, as well as autoimmune and inflammatory diseases that involve B cells in their pathology.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-904 | Anti-Human CD37 Recombinant Antibody (Otlertuzumab) | ELISA, IP, FC, FuncS, Neut, IF, ICC | VH - V-kappa - CH2 - CH3 |
There are currently no Customer reviews or questions for HPAB-1045-FY. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.